Medium-throughput Drug Screening of Patient-derived Organoids from Colorectal Peritoneal Metastases to Direct Personalized Therapy

V Narasimhan; JA Wright; M Churchill; T Wang; R Rosati; TRM Lannagan; L Vrbanac; AB Richardson; H Kobayashi; T Price; GXY Tye; J Marker; PJ Hewett; MP Flood; S Pereira; GA Whitney; M Michael; J Tie; S Mukherjee; C Grandori; AG Heriot; DL Worthley; RG Ramsay; SL Woods

Journal article

Medium-throughput Drug Screening of Patient-derived Organoids from Colorectal Peritoneal Metastases to Direct Personalized Therapy

V Narasimhan, JA Wright, M Churchill, T Wang, R Rosati, TRM Lannagan, L Vrbanac, AB Richardson, H Kobayashi, T Price, GXY Tye, J Marker, PJ Hewett, MP Flood, S Pereira, GA Whitney, M Michael, J Tie, S Mukherjee, C Grandori Show all

Clinical Cancer Research | AMER ASSOC CANCER RESEARCH | Published : 2020

DOI: 10.1158/1078-0432.CCR-20-0073

Abstract

Purpose: Patients with colorectal cancer with peritoneal metastases (CRPMs) have limited treatment options and the lowest colorectal cancer survival rates. We aimed to determine whether organoid testing could help guide precision treatment for patients with CRPMs, as the clinical utility of prospective, functional drug screening including nonstandard agents is unknown. Experimental Design: CRPM organoids (peritonoids) isolated from patients underwent parallel next-generation sequencing and medium-throughput drug panel testing ex vivo to identify specific drug sensitivities for each patient. We measured the utility of such a service including: success of peritonoid generation, time to cultiva..

View full abstract

University of Melbourne Researchers

Michael Michael Author

Jeanne Tie Author

Sandy Heriot Author

Rob Ramsay Author

Related Projects (1)

FROM THE STONE AGE TO THE STATE OF THE ART – MULTIDIMENSIONAL PRECISION MEDICINE FOR PERITONEAL CRC

Peritoneal cancer develops in the abdomen and may be present at primary diagnosis but can also arise from tumour cells that remain post-surg..

Grants

Awarded by National Cancer Institute

Funding Acknowledgements

This study was supported by grants from the National Health and Medical Research Council (APP1156391 to R. Rosati, D.L. Worthley, and S.L. Woods), Cancer Council SA Beat Cancer Project on behalf of its donors and the State Government of South Australia through the Department of Health (MCF0418 to S.L. Woods and D.L. Worthley), the Faculty of Health Science at the University of Adelaide (to S.L. Worthley), the Peter MacCallum Cancer Centre Foundation (to R. Rosati), and NCI (R01CA144288, U01CA217883 to C. Grandori). SEngine Precision Medicine provided organoid drug testing at no cost. We thank the patients and their families for taking part in this study; Prof. Cheri Ostroff for critical reading of the article; Dr. Andreas Shreiber and Paul Wang from the Australian Cancer Research Foundation Cancer Genomics Facility in the Centre for Cancer Biology, Adelaide for NGS analysis; and Dr. Thio Niko and Magnus Zethoven from the Bioinformatics Consulting Core in the Cancer Research Division at Peter MacCallum Cancer Centre, Melbourne for NGS analysis.